CAVERJECT

LOE Approaching

alprostadil

NDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

Prostaglandin Receptor Agonists

Pharmacologic Class:

Prostaglandin Analog

Indications (1)

Clinical Trials (4)

NCT01747928Phase 1Completed

Users Study Of The Caverject Delivery System

Started Mar 2013
48 enrolled
Healthy
NCT01008605Phase 3Completed

Caverject User Study

Started Feb 2011
48 enrolled
Erectile Dysfunction
NCT00619229Phase 3Terminated

Alprostadil in Maculopathy Study (AIMS)

Started Jul 2006
37 enrolled
Macular Degeneration
NCT00596752Phase 4Completed

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

Started Mar 2004
840 enrolled
Peripheral Arterial Occlusive Disease